Retatrutide: the triple agonist and what its Phase 2 data actually show

Retatrutide is the molecule that made people who follow obesity drugs sit up. If semaglutide acts on one incretin pathway and tirzepatide on two, retatrutide adds a third — it is a single peptide that agonizes the GIP, GLP-1 and glucagon receptors at once. The Phase 2 weight-loss numbers are the largest yet reported for a pharmacological agent. They are also, importantly, still Phase 2 numbers. Here is the precise state of the evidence.

What it is, and why a third receptor matters

Retatrutide (formerly LY3437943) is an investigational once-weekly injectable from Eli Lilly. The GLP-1 and GIP components drive the appetite-suppression and insulin-secretion effects familiar from semaglutide and tirzepatide. The novel piece is glucagon-receptor agonism: glucagon raises energy expenditure and promotes hepatic fat mobilization, so the design intent is to pair reduced calorie intake with increased calorie burn. That is the mechanistic theory. The trial below is what actually happened in people.

The headline: the Phase 2 obesity trial

In a 48-week, double-blind, randomized Phase 2 trial, 338 adults with obesity (and without diabetes) received retatrutide at one of several maintenance doses or placebo. At the highest dose (12 mg), participants lost a mean of about 24.2% of body weight, versus roughly 2% with placebo.^[1] At 48 weeks the weight-loss curve had not clearly plateaued at the top doses — participants were, on average, still losing weight when the study window closed. That is the detail driving the excitement: the trajectory suggests the ceiling had not yet been reached.

Those magnitudes exceed what semaglutide (about −15% in STEP 1) and tirzepatide (about −21% in SURMOUNT-1) reported. But the comparison must be read with real caution: this is a Phase 2 trial of a few hundred people over under a year, not a Phase 3 outcomes program. Cross-trial comparisons across different populations, durations and designs are suggestive, not definitive.

The diabetes signal

A parallel 36-week Phase 2 trial tested retatrutide in adults with type 2 diabetes. It produced substantial reductions in both HbA1c and body weight across doses, with dose-dependent glycemic improvement.^[2] So the metabolic effect is not confined to weight: the glucose data are consistent with the incretin components doing what incretin drugs do. Again, the read-out is a mid-stage proof-of-concept, not a cardiovascular or renal outcomes trial.

The honest caveats

Three things deserve emphasis. First, tolerability: like all incretin agents, gastrointestinal side effects (nausea, vomiting, diarrhea) were common and dose-related, and dose escalation matters. Second, the glucagon question: glucagon agonism can raise heart rate and, in theory, perturb glucose handling; the Phase 2 data were reassuring on net glycemia, but long-term cardiometabolic safety is exactly what later-phase trials exist to establish. Third, and most important, retatrutide is not approved anywhere as of this writing — it is in Phase 3 development. There is no long-term outcomes data, no established maintenance dosing outside trials, and nothing legitimately available outside a clinical study.

The honest bottom line

Retatrutide's Phase 2 weight-loss results are genuinely the strongest pharmacological signal reported to date, and the non-plateauing curve at 48 weeks is the most intriguing feature of all. But “strongest Phase 2 result” is a precise and limited claim. Whether that effect holds across larger populations and longer horizons — and whether the safety profile, glucagon component included, supports it — is what the ongoing Phase 3 program will decide. Until then, the appropriate posture is well-founded optimism, not a verdict.